EP2542540A1 - Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid - Google Patents

Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

Info

Publication number
EP2542540A1
EP2542540A1 EP11711672.3A EP11711672A EP2542540A1 EP 2542540 A1 EP2542540 A1 EP 2542540A1 EP 11711672 A EP11711672 A EP 11711672A EP 2542540 A1 EP2542540 A1 EP 2542540A1
Authority
EP
European Patent Office
Prior art keywords
febuxostat
crystalline form
ketone
reaction mixture
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11711672.3A
Other languages
German (de)
French (fr)
Inventor
Sarbjot Singh Sokhi
Asok Nath
Nitin Tandon
Mohan Prasad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP2542540A1 publication Critical patent/EP2542540A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Definitions

  • the present invention provides for crystalline Form R of 2-[3-cyano-4-(2- methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, and process for its preparation.
  • the present invention also includes a pharmaceutical composition, which includes Form R and its use in the chronic management of hyperuricemia in patients with gout.
  • 2-[3-Cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid is a non-purine xanthine oxidase inhibitor having the structure as represented by Formula I.
  • U.S. Patent No. 6,225,474 discloses crystalline Forms A, B, C, D and G of febuxostat prepared using a mixture of methanol, ethanol or propanol with water.
  • WO 2008/067773 discloses crystalline Forms H, I and J of febuxostat prepared using acetonitrile.
  • CN 101139325, CN 101085761, CN 101386605 and CN 101412700 disclose crystalline forms of febuxostat prepared using ethanol, ethyl acetate, acetone or 1,4- dioxane.
  • the present invention provides for crystalline Form R of febuxostat, which includes X-ray diffraction peaks at d-spacing of about 15.62, 15.23, 11.08, 6.93 and 3.43 A
  • Embodiments of this aspect may include one or more of the following features.
  • the crystalline Form may further include X-ray diffraction peaks at d-spacing of about 7.61, 7.04, 5.25, 4.32 and 3.40 A.
  • the present invention provides for crystalline Form R of febuxostat characterized by X-ray diffraction pattern as depicted in Figure- 1.
  • the present invention provides for Crystalline Form R of febuxostat characterized by DSC as depicted in Figure-2.
  • the present invention provides for Crystalline Form R of febuxostat characterized by TGA as depicted in Figure-3.
  • the present invention provides for Crystalline Form R of febuxostat characterized by IR spectrum as depicted in Figure 4.
  • the present invention provides for a process for the preparation of crystalline Form R of febuxostat.
  • the process includes:
  • Embodiments of this aspect may include one or more of the following features.
  • the ketone is acetone, dimethyl ketone, ethyl methyl ketone or methyl iso- butyl ketone.
  • the ketone may be ethyl methyl ketone.
  • the febuxostat may be contacted with the solvent at room temperature.
  • the reaction mixture may be heated to about 40°C to the reflux temperature of the solvent.
  • the reaction mixture may be stirred for about 5 minutes to about 30 minutes.
  • the reaction mixture may also be further cooled to about 5°C to about 25 °C.
  • the reaction mixture may also be further dried under reduced pressure at a temperature of about 35°C to about 60°C.
  • the present invention provides for a pharmaceutical composition, which includes crystalline Form R of febuxostat and one or more
  • the present invention also provides for the use of crystalline Form R of febuxostat in the manufacture of a medicament for use in chronic management of hyperuricemia in patients with gout.
  • Figure- 1 X-ray diffraction pattern (XRD) of crystalline Form R
  • Crystalline Form R of the present invention may be characterized by primary XRD 2 ⁇ peaks at about 5.65 (d-spacing at 15.62 A), 5.80 (15.23 A), 7.97 (11.08 A), 12.76 (6.93 A) and 25.92 (3.43 A) + 0.2° 2 ⁇ . It may be further characterized by XRD peaks at about 11.62 (7.61 A), 12.56 (7.04 A), 16.88 (5.25 A), 20.54 (4.32 A) and 26.19 (3.40 A) + 0.2° 2 ⁇ . Crystalline Form R may also be characterized by an endothermic maximum at 201 + 2°C observed during thermal analysis using DSC.
  • the febuxostat used for the preparation of the crystalline Form R of the present invention may be obtained by any of the methods known in the literature such as those described in U.S. Patent No. 5,614,520; U.S. Publication 2009/0203919; and U.S. Patent No. 7,541,475, which are incorporated herein by reference.
  • Febuxostat, to be used as starting material for the preparation of crystalline forms of the present invention may be obtained as a solution directly from a reaction in which it is formed and used as such without isolation.
  • contacting may include dissolving, slurrying, stirring or a combination thereof.
  • room temperature includes temperature in the range of about 15°C to about 35°C.
  • the solvent may be selected from the group comprising of C 3 -C 10 alcohols, carboxylic acids, chlorinated hydrocarbons, ketones, amides, sulphoxides, ethers, alkyl acetates, water or mixtures thereof.
  • C 3 -C 10 alcohols may include 1-propanol, 1-butanol or 2- butanol.
  • carboxylic acids may include formic acid, acetic acid or propionic acid.
  • chlorinated hydrocarbons may include dichloromethane or chloroform.
  • ketones may include acetone, dimethyl ketone, ethyl methyl ketone or methyl iso-butyl ketone.
  • Examples of ethers may include diethyl ether, ethyl methyl ether, di- isopropyl ether, tetrahydrofuran or 1,4-dioxane.
  • Examples of amides may include N, N- dimethylformamide or N, N-dimethylacetamide.
  • Examples of sulphoxides may include dimethyl sulfoxide or diethyl sulphoxide.
  • Examples of cyclic ethers may include tetrahydrofuran.
  • alkyl acetates may include methyl acetate, ethyl acetate, propyl acetate or butyl acetate.
  • the reaction mixture may be stirred for a period of about 1 minute to about 15 minutes followed by heating to a temperature of about 40°C to the reflux temperature of the solvent and further stirring for about 2 minutes to about 30 minutes. It may be cooled to a temperature of about 5°C to about 25°C, preferably, to about 15°C to about 20°C, over a period of about 10 minutes to about 2 hours, preferably, over a period of about 30 minutes. It may be further stirred for about 30 minutes to about 5 hours, preferably, for about 2 hours, and dried. Any suitable method of drying may be employed, such as, drying under reduced pressure, vacuum tray drying, air drying, or a combination thereof. Drying may be carried out at a temperature of about 20°C to about 60°C, preferably, at about 45°C, for a period of about 1 hour to about 8 hours, preferably, for about 5 hours.
  • crystalline Form R of the present invention is prepared by contacting febuxostat with a ketone solvent at a temperature of about 15°C to about 35°C.
  • the reaction mixture is stirred for about 1 minute to about 15 minutes, and the reaction mixture is heated to a temperature of about 40°C to the reflux temperature of the solvent. This is stirred for about 5 minutes to about 30 minutes. This is then cooled to a temperature of about 5°C to about 25°C in a period of about 10 minutes to about 2 hours, and then for about 30 minutes to about 5 hours; followed by drying.
  • the ketone solvent may be acetone, dimethyl ketone, ethyl methyl ketone or methyl iso-butyl ketone.
  • crystalline Form R of the present invention is prepared by contacting febuxostat with ethyl iso-butyl ketone at room temperature, stirring the reaction mixture for about 1 minute to about 15 minutes. The reaction mixture is then heated to a temperature of about 40°C to the reflux temperature of the solvent, and stirred for about 5 minutes to about 30 minutes. This is then cooled to a temperature of about 15°C to about 20°C over a period of 30 minutes. Finally, the reaction mixture is stirred for about 2 hours and then dried under reduced pressure at a temperature of about 45 °C for about 5 hours.
  • Crystalline Form R of the present invention is a highly pure, easy to filter, free- flowing solid.
  • crystalline Form R has a particle size of less than 100 ⁇ .
  • Crystalline Form R of the present invention is free of residual solvents, is stable towards polymorphic conversion and shows little or no variation in dissolution profile.
  • free of residual solvents refers to crystalline Form R of febuxostat containing less than 5000 ppm, preferably, less than 1000 ppm and more preferably, less than 500 ppm of residual solvents.
  • the crystalline Form R of febuxostat of the present invention may be converted into an amorphous form of febuxostat by evaporation of the solvent, spray drying, freeze - drying or lyophilization. Solvates, pseudomorphs and hydrates of crystalline Form R of the present invention are also included within the scope of the present invention.
  • the crystalline Form R of febuxostat of the present invention may be administered as part of a pharmaceutical composition for the chronic management of hyperuricemia in patients with gout. Any suitable route of administration may be employed for example peroral or parental.
  • the present invention also provides for a pharmaceutical composition which includes crystalline Form R of febuxostat, one or more pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients.
  • the excipients may be vegetable oils, oily esters, glycerin esters, alcohols, physiological saline, glycols, animal fat and oil, cellulose derivatives, polyvinyl pyrrolidone, dextrin, lactose, mannitol, sorbitol or starch.
  • vegetable oils may include corn oil, cotton seed oil, coconut oil, almond oil, peanut oil or olive oil.
  • oily esters may include glyceride oils or mineral oils.
  • Examples of glycerin esters may include tricaprylin or triacetin.
  • Examples of alcohols may include methanol, ethanol or propanol.
  • Examples of glycols may include propylene glycol or polyethylene glycol.
  • Examples of cellulose derivatives may include crystalline cellulose, hydroxypropyl cellulose,
  • the diluents may be calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate.
  • the crystalline Form R of febuxostat of the present invention may be formulated into capsules, hard capsules, tablets, granules, powder, suspension, solutions and syrups, injections, suppositories and external preparations.
  • Embodiments of the present invention are described by way of example to illustrate the process of invention. However, this is not intended in any way to limit the scope of the present invention. Several variants of the example would be evident to persons ordinarily skilled in the art which are within the scope of the present invention.
  • the X-ray diffraction patterns were recorded using Panalytical Expert PRO with Xcelerator as detector, 3-40 as scan range, 0.02 as step size and 3-40° 2 ⁇ as range.
  • DSC and TGA were recorded using Mettler Toledo DSC 82 le and Perkin Elmer TGA 7 instruments, respectively.
  • Febuxostat (3 g) was added to a round-bottomed flask containing ethyl methyl ketone (21 mL) at room temperature. The reaction mixture was stirred for about 3 minutes, followed by heating to about 50°C to about 55°C. The reaction mixture was stirred for about 5 minutes, cooled to about 15°C to about 20°C over a period of about 30 minutes, stirred for about 2 hours, filtered, washed with ethyl methyl ketone (3 mL) and dried under reduced pressure at a temperature of about 45 °C for about 5 hours to obtain crystalline Form R of febuxostat.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides crystalline Form R of 2-[3-cyano-4-(2- methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, process for its preparation, pharmaceutical composition comprising it and its use for the chronic management of hyperuricemia in patients with gout.

Description

POLYMORPH OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4- METHYLTHIAZOLE-5-CARBOXYLIC ACID
Field of the Invention
The present invention provides for crystalline Form R of 2-[3-cyano-4-(2- methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, and process for its preparation. The present invention also includes a pharmaceutical composition, which includes Form R and its use in the chronic management of hyperuricemia in patients with gout.
Background of the Invention
2-[3-Cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) is a non-purine xanthine oxidase inhibitor having the structure as represented by Formula I.
Formula I
Febuxostat is disclosed in U.S. Patent No. 5,614,520 and is marketed in the United
States under the brand name Uloric® for the chronic management of hyperuricemia in patients with gout. Crystalline forms of febuxostat are disclosed in U.S. Patent No.
6,225,474; WO 2008/067773; CN 101139325; CN 101085761; CN 101386605; and CN 101412700.
U.S. Patent No. 6,225,474 discloses crystalline Forms A, B, C, D and G of febuxostat prepared using a mixture of methanol, ethanol or propanol with water.
WO 2008/067773 discloses crystalline Forms H, I and J of febuxostat prepared using acetonitrile. CN 101139325, CN 101085761, CN 101386605 and CN 101412700 disclose crystalline forms of febuxostat prepared using ethanol, ethyl acetate, acetone or 1,4- dioxane.
Summary of the Invention
In one general aspect, the present invention provides for crystalline Form R of febuxostat, which includes X-ray diffraction peaks at d-spacing of about 15.62, 15.23, 11.08, 6.93 and 3.43 A
Embodiments of this aspect may include one or more of the following features. For example, the crystalline Form may further include X-ray diffraction peaks at d-spacing of about 7.61, 7.04, 5.25, 4.32 and 3.40 A.
In another general aspect, the present invention provides for crystalline Form R of febuxostat characterized by X-ray diffraction pattern as depicted in Figure- 1.
In another general aspect, the present invention provides for Crystalline Form R of febuxostat characterized by DSC as depicted in Figure-2.
In another general aspect, the present invention provides for Crystalline Form R of febuxostat characterized by TGA as depicted in Figure-3.
In another general aspect, the present invention provides for Crystalline Form R of febuxostat characterized by IR spectrum as depicted in Figure 4.
In another general aspect, the present invention provides for a process for the preparation of crystalline Form R of febuxostat. The process includes:
i) contacting febuxostat with a ketone to form a reaction mixture; and ii) isolating crystalline Form R.
Embodiments of this aspect may include one or more of the following features. For example, the ketone is acetone, dimethyl ketone, ethyl methyl ketone or methyl iso- butyl ketone. The ketone may be ethyl methyl ketone.
The febuxostat may be contacted with the solvent at room temperature. The reaction mixture may be heated to about 40°C to the reflux temperature of the solvent. The reaction mixture may be stirred for about 5 minutes to about 30 minutes. The reaction mixture may also be further cooled to about 5°C to about 25 °C. The reaction mixture may also be further dried under reduced pressure at a temperature of about 35°C to about 60°C.
In yet another general aspect, the present invention provides for a pharmaceutical composition, which includes crystalline Form R of febuxostat and one or more
pharmaceutically acceptable carriers, diluents or excipients.
In another general aspect, the present invention also provides for the use of crystalline Form R of febuxostat in the manufacture of a medicament for use in chronic management of hyperuricemia in patients with gout.
Brief Description of the Figures
Figure- 1: X-ray diffraction pattern (XRD) of crystalline Form R
Figure-2: Differential Scanning Calorimetry (DSC) of crystalline Form R
Figure-3: Thermogravimetric Analysis (TGA) of crystalline Form R
Figure-4: Infra-red spectrum (IR) of crystalline Form R
Detailed Description of the Invention
Crystalline Form R of the present invention may be characterized by primary XRD 2Θ peaks at about 5.65 (d-spacing at 15.62 A), 5.80 (15.23 A), 7.97 (11.08 A), 12.76 (6.93 A) and 25.92 (3.43 A) + 0.2° 2Θ. It may be further characterized by XRD peaks at about 11.62 (7.61 A), 12.56 (7.04 A), 16.88 (5.25 A), 20.54 (4.32 A) and 26.19 (3.40 A) + 0.2° 2Θ. Crystalline Form R may also be characterized by an endothermic maximum at 201 + 2°C observed during thermal analysis using DSC. It may be characterized by XRD pattern, DSC, TGA and IR as depicted in Figures 1, 2, 3 and 4, respectively. Table- 1 provides XRD peaks of crystalline Form R. Table- 1: X-Ray Diffraction Peaks of Crystalline Form R
The febuxostat used for the preparation of the crystalline Form R of the present invention may be obtained by any of the methods known in the literature such as those described in U.S. Patent No. 5,614,520; U.S. Publication 2009/0203919; and U.S. Patent No. 7,541,475, which are incorporated herein by reference. Febuxostat, to be used as starting material for the preparation of crystalline forms of the present invention, may be obtained as a solution directly from a reaction in which it is formed and used as such without isolation.
The term "contacting" may include dissolving, slurrying, stirring or a combination thereof.
The term "about", as used herein, includes variations in the range of + 10% in the temperature and time period.
The term "room temperature", as used herein, includes temperature in the range of about 15°C to about 35°C.
Febuxostat may be contacted with a solvent at about room temperature. The solvent may be selected from the group comprising of C3-C10 alcohols, carboxylic acids, chlorinated hydrocarbons, ketones, amides, sulphoxides, ethers, alkyl acetates, water or mixtures thereof. Examples of C3-C10 alcohols may include 1-propanol, 1-butanol or 2- butanol. Examples of carboxylic acids may include formic acid, acetic acid or propionic acid. Examples of chlorinated hydrocarbons may include dichloromethane or chloroform. Examples of ketones may include acetone, dimethyl ketone, ethyl methyl ketone or methyl iso-butyl ketone. Examples of ethers may include diethyl ether, ethyl methyl ether, di- isopropyl ether, tetrahydrofuran or 1,4-dioxane. Examples of amides may include N, N- dimethylformamide or N, N-dimethylacetamide. Examples of sulphoxides may include dimethyl sulfoxide or diethyl sulphoxide. Examples of cyclic ethers may include tetrahydrofuran. Examples of alkyl acetates may include methyl acetate, ethyl acetate, propyl acetate or butyl acetate.
The reaction mixture may be stirred for a period of about 1 minute to about 15 minutes followed by heating to a temperature of about 40°C to the reflux temperature of the solvent and further stirring for about 2 minutes to about 30 minutes. It may be cooled to a temperature of about 5°C to about 25°C, preferably, to about 15°C to about 20°C, over a period of about 10 minutes to about 2 hours, preferably, over a period of about 30 minutes. It may be further stirred for about 30 minutes to about 5 hours, preferably, for about 2 hours, and dried. Any suitable method of drying may be employed, such as, drying under reduced pressure, vacuum tray drying, air drying, or a combination thereof. Drying may be carried out at a temperature of about 20°C to about 60°C, preferably, at about 45°C, for a period of about 1 hour to about 8 hours, preferably, for about 5 hours.
In a particular embodiment, crystalline Form R of the present invention is prepared by contacting febuxostat with a ketone solvent at a temperature of about 15°C to about 35°C. The reaction mixture is stirred for about 1 minute to about 15 minutes, and the reaction mixture is heated to a temperature of about 40°C to the reflux temperature of the solvent. This is stirred for about 5 minutes to about 30 minutes. This is then cooled to a temperature of about 5°C to about 25°C in a period of about 10 minutes to about 2 hours, and then for about 30 minutes to about 5 hours; followed by drying. The ketone solvent may be acetone, dimethyl ketone, ethyl methyl ketone or methyl iso-butyl ketone.
In another embodiment, crystalline Form R of the present invention is prepared by contacting febuxostat with ethyl iso-butyl ketone at room temperature, stirring the reaction mixture for about 1 minute to about 15 minutes. The reaction mixture is then heated to a temperature of about 40°C to the reflux temperature of the solvent, and stirred for about 5 minutes to about 30 minutes. This is then cooled to a temperature of about 15°C to about 20°C over a period of 30 minutes. Finally, the reaction mixture is stirred for about 2 hours and then dried under reduced pressure at a temperature of about 45 °C for about 5 hours.
Crystalline Form R of the present invention is a highly pure, easy to filter, free- flowing solid. Preferably, crystalline Form R has a particle size of less than 100 μπι.
Variations in dissolution profiles may arise due to larger particle size. Crystalline Form R of the present invention is free of residual solvents, is stable towards polymorphic conversion and shows little or no variation in dissolution profile.
The term "free of residual solvents", as used herein, refers to crystalline Form R of febuxostat containing less than 5000 ppm, preferably, less than 1000 ppm and more preferably, less than 500 ppm of residual solvents.
The crystalline Form R of febuxostat of the present invention may be converted into an amorphous form of febuxostat by evaporation of the solvent, spray drying, freeze - drying or lyophilization. Solvates, pseudomorphs and hydrates of crystalline Form R of the present invention are also included within the scope of the present invention.
The crystalline Form R of febuxostat of the present invention may be administered as part of a pharmaceutical composition for the chronic management of hyperuricemia in patients with gout. Any suitable route of administration may be employed for example peroral or parental.
The present invention also provides for a pharmaceutical composition which includes crystalline Form R of febuxostat, one or more pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients. The excipients may be vegetable oils, oily esters, glycerin esters, alcohols, physiological saline, glycols, animal fat and oil, cellulose derivatives, polyvinyl pyrrolidone, dextrin, lactose, mannitol, sorbitol or starch. Examples of vegetable oils may include corn oil, cotton seed oil, coconut oil, almond oil, peanut oil or olive oil. Examples of oily esters may include glyceride oils or mineral oils. Examples of glycerin esters may include tricaprylin or triacetin. Examples of alcohols may include methanol, ethanol or propanol. Examples of glycols may include propylene glycol or polyethylene glycol. Examples of cellulose derivatives may include crystalline cellulose, hydroxypropyl cellulose,
hydroxypropylmethyl cellulose or methyl cellulose. The diluents may be calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate. The crystalline Form R of febuxostat of the present invention may be formulated into capsules, hard capsules, tablets, granules, powder, suspension, solutions and syrups, injections, suppositories and external preparations.
Embodiments of the present invention are described by way of example to illustrate the process of invention. However, this is not intended in any way to limit the scope of the present invention. Several variants of the example would be evident to persons ordinarily skilled in the art which are within the scope of the present invention.
Methods
The X-ray diffraction patterns were recorded using Panalytical Expert PRO with Xcelerator as detector, 3-40 as scan range, 0.02 as step size and 3-40° 2Θ as range. DSC and TGA were recorded using Mettler Toledo DSC 82 le and Perkin Elmer TGA 7 instruments, respectively.
IR spectrum was recorded using Perkin Elmer Spectrum one FT-IR spectrometer.
Example: Preparation of Crystalline Form R of Febuxostat
Febuxostat (3 g) was added to a round-bottomed flask containing ethyl methyl ketone (21 mL) at room temperature. The reaction mixture was stirred for about 3 minutes, followed by heating to about 50°C to about 55°C. The reaction mixture was stirred for about 5 minutes, cooled to about 15°C to about 20°C over a period of about 30 minutes, stirred for about 2 hours, filtered, washed with ethyl methyl ketone (3 mL) and dried under reduced pressure at a temperature of about 45 °C for about 5 hours to obtain crystalline Form R of febuxostat.
Yield: 2.4 g

Claims

We Claim:
1. Crystalline Form R of febuxostat comprising X-ray diffraction peaks at d-spacing of about 15.62, 15.23, 11.08, 6.93 and 3.43 A
2. The crystalline Form R according to claim 1 further comprising X-ray diffraction peaks at d-spacing of about 7.61, 7.04, 5.25, 4.32 and 3.40 A.
3. Crystalline Form R of febuxostat characterized by X-ray diffraction pattern as depicted in Figure- 1.
4. Crystalline Form R of febuxostat characterized by DSC as depicted in Figure-2.
5. Crystalline Form R of febuxostat characterized by TGA as depicted in Figure-3.
6. Crystalline Form R of febuxostat characterized by IR spectrum as depicted in Figure-4.
7. A process for the preparation of crystalline Form R of febuxostat comprising: i) contacting febuxostat with a ketone to form a reaction mixture; and ii) isolating crystalline Form R.
8. The process according to claim 7, wherein the ketone consists of acetone, dimethyl ketone, ethyl methyl ketone or methyl iso-butyl ketone.
9. The process according to claim 8, wherein the ketone consists of ethyl methyl ketone.
10. The process according to claim 7, wherein the febuxostat is contacted with the solvent at room temperature.
11. The process according to claim 7, wherein the reaction mixture is heated to about 40°C to the reflux temperature of the solvent.
12. The process according to claim 7, wherein the reaction mixture is stirred for about 5 minutes to about 30 minutes.
13. The process according to claim 7, wherein the reaction mixture is further cooled to about 5°C to about 25 °C.
14. The process according to claim 7, wherein the reaction mixture is further dried under reduced pressure at a temperature of about 35°C to about 60°C.
15. A pharmaceutical composition comprising crystalline Form R of febuxostat and one or more pharmaceutically acceptable carriers, diluents or excipients.
16. Use of crystalline Form R of febuxostat defined in any of claims 1-6, in the manufacture of a medicament for use in chronic management of hyperuricemia in patients with gout.
EP11711672.3A 2010-03-04 2011-02-24 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid Withdrawn EP2542540A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN488DE2010 2010-03-04
PCT/IB2011/050785 WO2011107911A1 (en) 2010-03-04 2011-02-24 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

Publications (1)

Publication Number Publication Date
EP2542540A1 true EP2542540A1 (en) 2013-01-09

Family

ID=43881251

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11711672.3A Withdrawn EP2542540A1 (en) 2010-03-04 2011-02-24 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

Country Status (4)

Country Link
EP (1) EP2542540A1 (en)
AU (1) AU2011222462A1 (en)
CA (1) CA2792036A1 (en)
WO (1) WO2011107911A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811912A1 (en) 2010-09-24 2012-03-29 Hetero Research Foundation Novel polymorphs of febuxostat
WO2012168948A2 (en) 2011-06-06 2012-12-13 Hetero Research Foundation Process for febuxostat
CN104114545B (en) * 2011-11-15 2018-06-01 迈兰实验室有限公司 It is used to prepare the method for Febuxostat polymorph
CZ27857U1 (en) 2014-12-12 2015-02-23 Zentiva, K.S. Formulation containing febuxostat solid solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085761A (en) 2007-06-29 2007-12-12 上海华拓医药科技发展股份有限公司 Febuxotat microcrystal and compositions thereof
CN101412700A (en) 2007-10-19 2009-04-22 上海医药工业研究院 Crystal form and preparation of febuxostat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG86971A1 (en) 1990-11-30 2002-03-19 Teijin Ltd 2-arylthiazole derivatives and pharmaceutical composition thereof
RU2198169C3 (en) 1998-06-19 2017-07-20 Тейдзин Лимитед POLYMORPHIC FORMS 2- (3-CYAN-4-ISOBUTYLOXYPHENYL) -4-METHYL-5-TIAZOLKARBONIC ACID AND METHODS FOR THEIR
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
JP5193863B2 (en) 2006-06-23 2013-05-08 帝人ファーマ株式会社 Process for producing crystalline polymorph of 2- (3-cyano-4-isobutyloxyphenyl) -4-methyl-5-thiazolecarboxylic acid
CN101139325B (en) 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-cyano-4-isobuoxy phenyl)4-methyl-5-thiazole aminic acid crystal and preparation method thereof
CN1970547B (en) 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 Novel febuxostat crystal form and its preparation method
CN101386605B (en) 2008-10-23 2010-09-08 中国科学院上海药物研究所 Febustat novel crystal and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085761A (en) 2007-06-29 2007-12-12 上海华拓医药科技发展股份有限公司 Febuxotat microcrystal and compositions thereof
CN101412700A (en) 2007-10-19 2009-04-22 上海医药工业研究院 Crystal form and preparation of febuxostat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011107911A1

Also Published As

Publication number Publication date
WO2011107911A1 (en) 2011-09-09
CA2792036A1 (en) 2011-09-09
AU2011222462A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2010083752A1 (en) High-purity febuxostat and the method for preparation
CN109311832B (en) Pamoic acid salt of vortioxetine and crystal forms thereof
CA2375017C (en) Hydrochloride of fused-heterocycle compound
PL218982B1 (en) α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE
US20130190366A1 (en) Substantially pure salts of febuxostat and processes for preparation thereof
AU2003224779A1 (en) Lansoprazole polymorphs and processes for preparation thereof
AU2009215377A1 (en) Novel polymorphs and processes for their preparation
IL263631A (en) Aldose reductase inhibitors and methods of use thereof
EP2542540A1 (en) Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
WO2008015563A2 (en) Salts of rosuvastatin and processes for their preparation
WO2012140632A1 (en) Febuxostat solid dispersion
CA1244431A (en) Phenylpiperazine derivatives and process for producing the same
WO2012098501A1 (en) Febuxostat co-crystals
US10385017B2 (en) Pyrrole compound, compositions and process for preparation thereof
WO2011080651A2 (en) Polymorphic forms of febuxostat
WO2004089948A1 (en) Novel crystalline forms of ziprasidone hydrochloride
CN1863799B (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
TW201900646A (en) Methanesulfonate polycrystal of type 5 phosphodiesterase inhibitor, preparation method and application thereof
JP2001039976A (en) Hydrochloride of condensed heterocyclic compound
US20060004027A1 (en) Drying process for preparing crystalline solid famciclovir
WO2016001093A1 (en) Process for making microcrystalline dimethyl fumarate
JP2002220336A (en) Preventive and therapeutic agents for diabetes containing condensed heterocyclic compound
JP2010159293A (en) Sodium salt of azo derivative of 5-aminosalicylic acid
EP2726484A1 (en) Solid dispersions of sitagliptin and processes for their preparation
CN113121331B (en) Phenoxy aromatic acid compounds with cyclopropyl and pharmaceutically acceptable salts thereof, and preparation methods and applications thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

TPAC Observations by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17P Request for examination filed

Effective date: 20121004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130430